Evidence map›Paper›PMID 24596683›Full record

ArticleFrontiers in oncology2014

Can Radiosensitivity Associated with Defects in DNA Repair be Overcome by Mitochondrial-Targeted Antioxidant Radioprotectors.

Joel S Greenberger, Hebist Berhane, Ashwin Shinde, Byung Han Rhieu, Mark Bernard, Peter Wipf, Erin M Skoda, Michael W Epperly

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. FANCD2 protects against bone marrow injury from ferroptosis.Biochemical and biophysical research communications · 2016
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Joel S GreenbergerDepartment of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.
Hebist BerhaneDepartment of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.
Ashwin ShindeDepartment of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.
Byung Han RhieuDepartment of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.
Mark BernardDepartment of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.
Peter WipfDepartment of Chemistry and Center for Chemical Methodologies and Library Development, University of Pittsburgh , Pittsburgh, PA , USA.
Erin M SkodaDepartment of Chemistry and Center for Chemical Methodologies and Library Development, University of Pittsburgh , Pittsburgh, PA , USA.
Michael W EpperlyDepartment of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.
Shadyside Hospital · USUniversity of Pittsburgh Medical Center · USUniversity of Pittsburgh · USUPMC Hillman Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation oncologists have observed variation in normal tissue responses between patients in many instances with no apparent explanation. The association of clinical tissue radiosensitivity with specific genetic repair defects (Wegner's syndrome, Ataxia telangiectasia, Bloom's syndrome, and Fanconi anemia) has been well established, but there are unexplained differences between patients in the general population with respect to the intensity and rapidity of appearance of normal tissue toxicity including radiation dermatitis, oral cavity mucositis, esophagitis, as well as differences in response of normal tissues to standard analgesic or other palliative measures. Strategies for the use of clinical radioprotectors have included modalities designed to either prevent and/or palliate the consequences of radiosensitivity. Most prominently, modification of total dose, fraction size, or total time of treatment delivery has been necessary in many patients, but such modifications may reduce the likelihood of local control and/or radiocurability. As a model system in which to study potential radioprotection by mitochondrial-targeted antioxidant small molecules, we have studied cell lines and tissues from Fanconi anemia (Fancd2(-/-)) mice of two background strains (C57BL/6NHsd and FVB/N). Both were shown to be radiosensitive with respect to clonogenic survival curves of bone marrow stromal cells in culture and severity of oral cavity mucositis during single fraction or fractionated radiotherapy. Oral administration of the antioxidant GS-nitroxide, JP4-039, provided significant radioprotection, and also ameliorated distant bone marrow suppression (abscopal effect of irradiation) in Fancd2 (-/-) mice. These data suggest that radiation protection by targeting the mitochondria may be of therapeutic benefit even in the setting of defects in the DNA repair process for irradiation-induced DNA double strand breaks.

Indexed as

clinical radiosensitivityFanconi anemiaGS-nitroxidemitochondriaradioprotectors

Identifiers

PMID24596683
PMCPMC3926189
OpenAlexW2132950999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.